Evidence map›Paper›PMID 35387772›Full record

ArticleBMJ (Clinical research ed.)2022

Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study.

Ioannis Katsoularis, Osvaldo Fonseca-Rodríguez, Paddy Farrington, Hanna Jerndal, Erling Häggström Lundevaller, Malin Sund, Krister Lindmark, Anne-Marie Fors Connolly

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in BMJ (Clinical research ed.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06695377 (Thromboembolic Complications Post-COVID-19), which is not on this map. Cited by 214 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
214citing papers in PubMed, 8 pooled it
37.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06695377 completednot on this map

Thromboembolic Complications Post-COVID-19: What is the Risk in Mild-Moderate Cases?

TypeobservationalSponsorMarmara University Pendik Training and Research HospitalRan2022 to 2022Enrolled961ConditionsCOVID 19, Thromboembolic and Bleeding Complications, Thromboembolism, Venous, Post COVID-19
3 · Its place in the literature

Who cites it

214 citing papers in PubMed, 8 syntheses or guidelines pooled it, 385 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Are Pre-Hospitalization ECG Abnormalities Associated With Increased Mortality in COVID-19 Patients? A Quantitative Systematic Literature Review.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2024
    Pooled it
  7. Pooled it
  8. Antiplatelet agents for the treatment of adults with COVID-19.The Cochrane database of systematic reviews · 2023
    Pooled it
  9. Efficacy of Atorvastatin Against Venous Thromboembolism After Total Hip Arthroplasty.Journal of musculoskeletal & neuronal interactions · 2025
    Trial
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

154 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Ioannis KatsoularisDepartment of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
Osvaldo Fonseca-RodríguezDepartment of Clinical Microbiology, Umeå University, 90187 Umeå, Sweden.
Paddy FarringtonSchool of Mathematics and Statistics, The Open University, Milton Keynes, UK.
Hanna JerndalDepartment of Clinical Microbiology, Umeå University, 90187 Umeå, Sweden.
Erling Häggström LundevallerUmeå School of Business, Economics and Statistics, Umeå University, Umeå, Sweden.
Malin SundDepartment of Surgical and Perioperative Sciences/Surgery, Umeå University, Umeå, Sweden.
Krister LindmarkDepartment of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
Anne-Marie Fors ConnollyDepartment of Clinical Microbiology, Umeå University, 90187 Umeå, Sweden anne-marie.fors.connolly@umu.se.ORCID 0000-0001-9215-4047
Umeå University · SEThe Open University · GBUniversity of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo quantify the risk of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19.

designSelf-controlled case series and matched cohort study.

settingNational registries in Sweden.

participants1 057 174 people who tested positive for SARS-CoV-2 between 1 February 2020 and 25 May 2021 in Sweden, matched on age, sex, and county of residence to 4 076 342 control participants. MAIN OUTCOMES MEASURES: Self-controlled case series and conditional Poisson regression were used to determine the incidence rate ratio and risk ratio with corresponding 95% confidence intervals for a first deep vein thrombosis, pulmonary embolism, or bleeding event. In the self-controlled case series, the incidence rate ratios for first time outcomes after covid-19 were determined using set time intervals and the spline model. The risk ratios for first time and all events were determined during days 1-30 after covid-19 or index date using the matched cohort study, and adjusting for potential confounders (comorbidities, cancer, surgery, long term anticoagulation treatment, previous venous thromboembolism, or previous bleeding event).

resultsCompared with the control period, incidence rate ratios were significantly increased 70 days after covid-19 for deep vein thrombosis, 110 days for pulmonary embolism, and 60 days for bleeding. In particular, incidence rate ratios for a first pulmonary embolism were 36.17 (95% confidence interval 31.55 to 41.47) during the first week after covid-19 and 46.40 (40.61 to 53.02) during the second week. Incidence rate ratios during days 1-30 after covid-19 were 5.90 (5.12 to 6.80) for deep vein thrombosis, 31.59 (27.99 to 35.63) for pulmonary embolism, and 2.48 (2.30 to 2.68) for bleeding. Similarly, the risk ratios during days 1-30 after covid-19 were 4.98 (4.96 to 5.01) for deep vein thrombosis, 33.05 (32.8 to 33.3) for pulmonary embolism, and 1.88 (1.71 to 2.07) for bleeding, after adjusting for the effect of potential confounders. The rate ratios were highest in patients with critical covid-19 and highest during the first pandemic wave in Sweden compared with the second and third waves. In the same period, the absolute risk among patients with covid-19 was 0.039% (401 events) for deep vein thrombosis, 0.17% (1761 events) for pulmonary embolism, and 0.101% (1002 events) for bleeding.

conclusionsThe findings of this study suggest that covid-19 is a risk factor for deep vein thrombosis, pulmonary embolism, and bleeding. These results could impact recommendations on diagnostic and prophylactic strategies against venous thromboembolism after covid-19.

Indexed as

COVID-19Pulmonary EmbolismVenous ThromboembolismVenous ThrombosisAnticoagulantsCohort StudiesHemorrhageHumansRisk FactorsSARS-CoV-2Anticoagulants

Identifiers

PMID35387772
PMCPMC8984137
OpenAlexW4223448922

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.